STUDIES by others have indicated that attenuated strain high passage virus-77 (HPV-77) or HPV-77 derived attenuated rubella vaccines are capable of inducing significant (fourfold or greater) increases in hemagglutination inhibiting (HI) and neutralizing antibody titers in at least 95% of susceptible children.1-3 Although this acquisition of antibody is often accompanied by pharyngeal shedding of the vaccine viruses, spread of these viruses to susceptible contacts has not been reported.1-3
To estimate the protective efficacy of HPV-77 induced antibodies, Meyer et al1 challenged five children by intranasal administration of pharyngeal secretions containing 100 tissue culture interfering dose50's (InD50) of rubella virus 8 to 12 months after the five had received HPV-77 vaccine. Although none of these five children with HPV-77 induced antibodies developed clinical rubella or shed rubella virus after challenge with "wild" virus, two had significant increases in HI, neutralizing, and complement fixing (CF) antibodies.1
Wilkins J, Leedom JM, Portnoy B, Salvatore MA. Reinfection With Rubella Virus Despite Live Vaccine Induced Immunity: Trials of HPV-77 and HPV-80 Live Rubella Virus Vaccines and Subsequent Artificial and Natural Challenge Studies. Am J Dis Child. 1969;118(2):275–294. doi:10.1001/archpedi.1969.02100040277025
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: